The global vaginitis therapeutics market size is projected to register a high CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the rising need for enhanced healthcare infrastructure, rising awareness about women's health, and the introduction of new treatments by major pharmaceutical companies.
Vaginitis refers to a range of health conditions or disorders occurred among women that are related to morbidity due to prolonged undiagnosed situation. Vaginitis is a vaginal problem that causes itchiness, pain, and discharge. The most common types of vaginitis include candida infections, tyrichomoniasis vaginitis, bacterial vaginosis, viral vaginitis, and chlamydia vaginitis. In recent years, extensive research has resulted in the development of diagnostic tools as well as treatment options for all types of vaginitis. Around one-third of the women population in the world are likely to develop vaginitis symptoms at some point. During the reproductive years in particular, women are especially vulnerable to vaginitis as a change in the balance of bacteria and yeast in the vaginal area can cause vaginitis. As per the Centers for Disease Control and Prevention (CDC) reports, more than 13 out of every 100 women are addicted to smoking cigarettes. Scientists associated with the National Institute of Allergy and Infectious Diseases (NIAID) are engaged to develop a test for yeast infection in order to give suitable antifungal treatment.
In addition, the Division of Intramural Population Health Research in NICHD, researchers are examining many aspects of the relationship between bacterial vaginosis and pregnancy outcome using both old and new data. Various government and non-government organizations, including the World Health Organization and the European Institute of Women's Health (EIWH), have launched campaigns to raise awareness about women's health.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing usage of antibiotics and growing research & development initiatives for precise diagnosis are projected to boost the market growth during the forecast period.
- Increasing women's health awareness as well as the introduction of new drugs by major pharmaceutical companies are anticipated to spur the market expansion during the forecast period.
- Rising demand for improved healthcare infrastructure and development of innovative diagnostic kits is expected to fuel the market expansion in coming years.
- Low healthcare budgets and policies in some developing countries is anticipated to impede the market growth.
- Patent expiration of branded drugs and the introduction of generic drugs are estimated to hinder the market growth.
Key Players
- Merck & Co.
- Pfizer, Inc.
- Bayer AG
- Novartis International AG
- Symbiomix Therapeutics, Inc.
- Lupin Pharmaceuticals, Inc.
- Mission Pharmacal Company
Competitive Landscape
Key players competing in the global vaginitis therapeutics market include Merck & Co.; Pfizer, Inc.; Bayer AG; Novartis International AG; Symbiomix Therapeutics, Inc.; Lupin Pharmaceuticals, Inc.; and Mission Pharmacal Company.
Majority of these competitors are taking up initiatives including as collaborations, new drug development, mergers and acquisitions, and commercial expansion in emerging markets to enhance their market positions. Lupin Pharmaceuticals, for instance, acquired Symbiomix Therapeutics in October 2017 to expand its product portfolio. Pfizer Inc. announced a reconsideration of strategy in October 2017 to examine strategic alternatives for spinning off its Consumer Healthcare Business into a strategic plan.
To Get a New Sample Request: https://growthmarketreports.com/request-sample/1982
Contact Us
- Growth Market Reports
- Phone: +1 909 414 1393
- Email: sales@growthmarketreports.com
- Web: https://growthmarketreports.com
